12 Best Low-Priced Pharma Stocks to Buy Right Now

In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.

Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies. Some cheap stocks are owned by businesses in high-growth sectors that are profiting from long-term structural trends, but not all of them are a good deal. Finding these chances, however, necessitates negotiating a volatile macroeconomic landscape.

One of the defining themes of 2026 has been the conflict in the Middle East. On June 15, Reuters reported in its article, “Iran deal could expand market gains, with consumer shares, small caps seen benefiting,” that easing geopolitical tensions and lower oil prices could boost consumer spending while reducing inflationary pressures and Treasury yields. As a result, economically sensitive sectors such as consumer stocks, small-cap companies, and energy-dependent markets were expected to benefit, potentially broadening market leadership beyond AI-driven technology stocks. JPMorgan strategists noted,

“If our positive macro view plays out – underpinned by strong earnings, stable inflation expectations, and an easing of geopolitical risks in the second half – cyclicals should remain well positioned to outperform through year-end.”

However, doubt was rekindled on June 20 when Reuters reported that Iran had closed the Strait of Hormuz due to suspected ceasefire violations.

Many analysts continue to be optimistic about stocks in spite of these dangers. Sébastien Page, T. Rowe Price Head of Global Multi-Asset & CIO, told CNBC on May 13 that historic market highs are not trustworthy sell signals, pointing out that expected S&P 500 profits growth increased from 13% at the end of March to 27%. His firm continues to favor US large-cap growth stocks, citing attractive valuations and strong AI-driven earnings. Meanwhile, on May 12, Chris Veronne of Strategas cautioned that weakness in banks and consumer stocks deserves close attention, though the lack of a significant rotation into defensive sectors such as consumer staples and healthcare suggests investors have not yet turned broadly risk-averse.

With that said, let’s now take a look at the best low-price pharma stocks.

Our Methodology

For our methodology, we screened for pharmaceutical stocks priced below $50, based on the last close price as of June 24, with positive analyst upside. From this universe, we selected the 10 stocks with the most recent news and developments and ranked them in ascending order based on the number of hedge funds holding each stock as of Q1 2026, according to Insider Monkey’s database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Here is our list of the 12 best low-priced pharma stocks to buy right now.

12. Medicus Pharma Ltd. (NASDAQ:MDCX)

Number of Hedge Fund Holders: 4

Stock Price: $0.42

Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation request with the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.

The submission follows the company’s previously filed Orphan Drug Designation application and ongoing FDA review of its registrational study design. MDCX reported that recent Phase 2 results demonstrated encouraging clinical and complete response rates while maintaining a favorable safety profile. If granted, the designation could support the company’s regulatory strategy and potentially provide eligibility for a Rare Pediatric Disease Priority Review Voucher, subject to future FDA approval.

Separately, Medicus Pharma Ltd. (NASDAQ:MDCX) announced earlier on June 8 that it had filed a substantial modification application through the European Union CTIS for the planned Phase 2b study of Teverelix in advanced prostate cancer. The study is intended to refine dose selection while further evaluating the therapy’s pharmacokinetics, pharmacodynamics, efficacy, and safety before registrational development. The program is focused on patients with elevated cardiovascular risk who require androgen deprivation therapy and builds on the company’s previous regulatory discussions with the FDA regarding its clinical development strategy for advanced prostate cancer.

Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotechnology company focused on advancing early-stage therapeutic candidates through clinical development and partnering with larger pharmaceutical companies for commercialization.

11. High Tide Inc. (NASDAQ:HITI)

Number of Hedge Fund Holders: 9

Stock Price: $2.21

High Tide Inc. (NASDAQ:HITI) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that HITI reported record second-quarter fiscal 2026 financial results. The corporation reported that its revenue increased 30% year over year to $179.3 million, while gross profit climbed 36% to $48.4 million, with gross margin improving to 27%. Adjusted EBITDA reached a record $13.9 million, up 73% from the prior year, and income from operations rose 554% to $6.1 million. The company also generated $1.5 million in free cash flow and reported positive net income. Meanwhile, Cabana Club membership surpassed 2.65 million, and the Canna Cabana retail network expanded to 221 stores across Canada.

Additionally, on the same day, High Tide Inc. (NASDAQ:HITI) entered into a definitive agreement to acquire 100% of J. Supply Holdings Inc., operating as Northern Helm, in a transaction valued at $7.74 million. The deal includes four cannabis retail stores in Ontario and is expected to expand the company’s Canna Cabana network to 228 locations nationwide, including 103 stores in Ontario. The acquisition consideration consists of approximately $3.2 million in assumed debt, about $1.83 million in cash, and roughly $2.75 million in High Tide common shares. The purchase price represents 4.5x the stores’ annualized adjusted EBITDA.

High Tide Inc. (NASDAQ:HITI) is a cannabis company operating retail, e-commerce, and medical distribution businesses. As Canada’s largest cannabis retailer, it is expanding internationally, including into Germany’s medical cannabis market.

10. Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Number of Hedge Fund Holders: 17

Stock Price: $5.80

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 16 that Barrington increased its price target on LFCR to $6.50 from $6.00 while reaffirming an Outperform rating on the shares. The firm’s updated outlook followed LFCR’s announcement of a new agreement with a global pharmaceutical company, marking its second such partnership within two weeks. Barrington noted that these agreements demonstrate the company’s ability to broaden its clinical development footprint while successfully advancing its long-term strategic objectives.

On June 15, Lifecore Biomedical, Inc. (NASDAQ:LFCR) disclosed a new agreement with a global pharmaceutical company under which it will provide technical transfer services for the commercial manufacturing of an injectable suspension therapy for neurological disorders. The contract represents the company’s seventh late-stage program agreement secured within the previous seven months, reflecting continued growth in its development pipeline. The selection also highlights LFCR’s expertise in manufacturing complex, high-viscosity injectable formulations and reinforces its position as a contract development and manufacturing partner for multinational pharmaceutical companies seeking specialized production capabilities in the United States.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals, complex formulations, and injectable-grade hyaluronic acid production.

9. Takeda Pharmaceutical Company Limited (NYSE:TAK)

Number of Hedge Fund Holders: 18

Stock Price: $15.72

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 23 that TAK announced positive topline findings from its Phase 3 LATITUDE Atlas study evaluating zasocitinib, an investigational oral TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis. The trial demonstrated that zasocitinib outperformed deucravacitinib on the primary endpoint, achieving superior PASI 100 response rates at Week 16. The therapy also met all major secondary endpoints, including PASI 90 and Static Physician’s Global Assessment 0 responses. Zasocitinib maintained a favorable safety and tolerability profile throughout the study, with no new safety concerns identified. The global trial enrolled 606 participants across eight countries, including 73 patients treated at 18 Canadian sites.

Separately, earlier on June 9, Takeda Pharmaceutical Company Limited (NYSE:TAK) announced that the U.S. Food and Drug Administration had accepted its supplemental Biologics License Application for intravenous ENTYVIO for pediatric patients aged 2 years and older with moderately to severely active ulcerative colitis and Crohn’s disease. The application is now under FDA review, with a Prescription Drug User Fee Act target action date expected in the first quarter of 2027. If approved, ENTYVIO IV could become the only gut-focused therapy option available for this pediatric population. The milestone highlights Takeda’s continued efforts to expand treatment options and address unmet needs for children and adolescents living with inflammatory bowel diseases.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a global biopharmaceutical company and one of Asia’s largest pharmaceutical firms, focused on developing innovative medicines across multiple therapeutic areas.

8. Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Number of Hedge Fund Holders: 19

Stock Price: $1.06

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the FDA’s Orange Book and notification of eligibility for a five-year extension of a composition of matter patent. The additions enhance the company’s existing patent portfolio, which now includes 14 Orange Book-listed patents covering Vafseo with protection extending through 2036. These developments further support the company’s efforts to protect the long-term value and commercial potential of the therapy.

Earlier on May 7, Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported its first-quarter 2026 financial results, highlighting continued progress for Vafseo and its kidney disease pipeline. Vafseo net product revenue reached $15.8 million during the quarter, while the number of patients using the therapy increased approximately 60% compared with the end of the prior quarter. The company also reported around 1,025 prescribers, representing a 28% increase from Q4 2025. Total first-quarter revenue was $53.5 million, compared with $57.3 million in the same period last year. AKBA continued advancing clinical programs, including praliciguat in FSGS and AKB-097 in rare kidney diseases, while maintaining cash resources of approximately $162.6 million as of March 31, 2026.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease.

7. GSK plc (NYSE:GSK)

Number of Hedge Fund Holders: 31

Stock Price: $51.99

GSK plc (NYSE:GSK) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 24 that GSK announced that Harmony Row Acquisition Co., an indirect wholly owned subsidiary, has formally launched a tender offer to acquire all outstanding Class A and Class B common shares of Nuvalent, Inc. (NASDAQ). Under the offer, Nuvalent shareholders would receive $124.00 per share in cash, subject to applicable withholding taxes and the conditions outlined in the offer documents. The tender offer is being carried out under the previously announced merger agreement signed on June 9, 2026, representing the next step toward completing the planned acquisition of Nuvalent.

In another commercial initiative, on June 1, GSK plc (NYSE:GSK)’s ViiV Healthcare introduced its PrEP Wisdom campaign to help people better understand long-acting injectable HIV prevention beyond dosing schedules alone. The awareness effort encourages informed decision-making by providing broader educational information about HIV pre-exposure prophylaxis (PrEP). The campaign also features television personality and longtime HIV and LGBTQ advocate Michelle Visage, supporting ViiV Healthcare’s efforts to expand public awareness and engagement around HIV prevention through educational outreach.

GSK plc (NYSE:GSK) is a global biopharmaceutical company developing vaccines and specialty medicines, with a focus on infectious diseases, HIV, respiratory/immunology, and oncology.

6. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Number of Hedge Fund Holders: 34

Stock Price: $17

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 25 that Guggenheim raised its price target on AMLX to $40 from $30 while reaffirming its Buy rating. The firm also elevated the stock to its Best Idea designation ahead of the anticipated Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, expected in the third quarter. Guggenheim expressed confidence that the pivotal study will produce favorable outcomes, supporting avexitide’s commercial prospects and positioning the therapy to capture a significant share of the estimated $6 billion-plus U.S. post-bariatric hypoglycemia market.

Just two days prior, on June 23, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial evaluating AMX0114 at the European Network to Cure ALS Meeting 2026. The study showed that AMX0114 was not associated with drug-related serious adverse events or serious neurological adverse events in Cohort 1. The safety results support continued testing of higher dose levels in the ongoing multiple ascending dose study. Biomarker assessments, including spectrin breakdown product 145, neurofilament light, and phosphorylated neurofilament heavy, remained close to baseline levels. Cohort 1 evaluated the lowest dose, with future cohorts planned to assess higher doses.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and rare diseases, focusing on innovative treatments for conditions with high unmet medical needs.

Click to continue reading and see the 5 Best Low-Priced Pharma Stocks to Buy Right Now.

Disclosure: None. None. Follow Insider Monkey on Google News.